TrimRX
US$ 22.36
glp 1 timeline Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions Timeline of critical milestones in
Description
March 25, 2024
Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products
Mounjaro hit $23 billion, and Zepbound added $13.5 billion
Researchers and leading pharma scientists now ask: could GLP-1s be our first true longevity drugs
Eat less, move more is not a long-term weight management solution
